| Literature DB >> 18710712 |
Peter R Brinsden1, Veronica Alam, Beatrice de Moustier, Patrick Engrand.
Abstract
In this randomized, double-blind, placebo-controlled, multicenter study, women (n = 149) with a history of at least two unexplained implantation failures after assisted reproductive techniques received recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days, or placebo. The clinical pregnancy rate after ET was significantly lower in patients receiving recombinant human leukemia inhibitory factor than in those receiving placebo (17.6% vs. 34.0%, respectively).Entities:
Mesh:
Substances:
Year: 2008 PMID: 18710712 DOI: 10.1016/j.fertnstert.2008.06.047
Source DB: PubMed Journal: Fertil Steril ISSN: 0015-0282 Impact factor: 7.329